Ferulic Acid Carbamate Derivatives for Alzheimer's Disease

Ferulic Acid Carbamate Derivatives for Alzheimer's Disease

Overview

Ferulic Acid Carbamate Derivatives for Alzheimer's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ferulic Acid Carbamate Derivatives for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>BuChE IC₅₀ (nM)</td>
</tr>
<tr>
<td class="label">5c</td>
<td>15.2</td>
</tr>
<tr>
<td class="label">5e</td>
<td>18.7</td>
</tr>
<tr>
<td class="label">5g</td>
<td>22.4</td>
</tr>
<tr>
<td class="label">5h</td>
<td>28.1</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Donepezil/Rivastigmine</td>
</tr>
<tr>
<td class="label">Primary target</td>
<td>AChE (+ weak BuChE)</td>
</tr>
<tr>
<td class="label">Antioxidant</td>
<td>No</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>AChE > BuChE</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Moderate</td>
</tr>
</table>

Ferulic acid carbamate derivatives represent a novel class of dual-targeting therapeutics for Alzheimer's disease (AD) that simultaneously inhibit butyrylcholinesterase (BuChE) and activate the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway. This approach addresses two key pathological hallmarks of AD: cholinergic deficit and oxidative stress.

The lead compounds from this series, particularly 5c, 5g, and 5h, demonstrate exceptional BuChE selectivity (>150-fold over acetylcholinesterase/AChE), neuroprotective effects against oxidative damage and amyloid-beta toxicity, and in vivo efficacy in transgenic AD models["@liu2019"].

Ferulic Acid: The Parent Compound

Ferulic acid (4-hydroxy-3-methoxycinnamic acid) is a natural phenolic compound found in various plant sources including wheat, rice, oats, and fruits. It exhibits well-documented neuroprotective properties:

• Antioxidant activity: Scavenges reactive oxygen species (ROS) and enhances endogenous antioxidant defenses
• Anti-inflammatory effects: Modulates NF-κB signaling and reduces neuroinflammation
• Anti-amyloid properties: Inhibits Aβ aggregation and reduces plaque formation
• Neuroprotection: Protects neurons against various toxic insults including oxidative stress and excitotoxicity

Carbamate Derivative Design

The carbamate derivative strategy involves conjugating ferulic acid with carbamate moieties to improve:

Structure-Activity Relationships (SAR)

Key findings from the SAR studies include[@lao2026]:

• Substitutions at the para-position of the phenyl ring influence both BuChE selectivity and Nrf2 activation
• Compound 5c showed >150-fold selectivity for BuChE over AChE
• The carbamate linkage is critical for both cholinesterase inhibition and maintaining antioxidant properties
• Optimal chain length and terminal group modification enhance CNS drugability

BuChE Inhibition Mechanism

Butyrylcholinesterase in Alzheimer's Disease

BuChE (also known as pseudocholinesterase or pseudo-acetylcholinesterase) is increasingly recognized as a therapeutically important target in AD[@kumar2020]:

• Cholinergic hypothesis extension: While AChE activity decreases in early AD, BuChE activity progressively increases with disease progression
• Amyloid interaction: BuChE co-localizes with amyloid plaques and may accelerate Aβ aggregation
• Glial cell association: BuChE is expressed in activated microglia and astrocytes surrounding plaques

Mechanism of Carbamate Inhibition

Carbamate derivatives inhibit BuChE through a reversible carbamylation mechanism:

The >150-fold selectivity for BuChE over AChE observed in compounds 5c and 5e is particularly valuable because:

• AChE inhibition can cause peripheral cholinergic side effects
• Selective BuChE inhibition preserves normal cholinergic signaling while targeting pathological activity
• This profile may be especially beneficial in moderate-to-severe AD where BuChE activity is elevated

Nrf2 Activation Pathway

The Nrf2-ARE Pathway in Neurodegeneration

The Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway is the master regulator of cellular antioxidant response[@sandberg2021]:

• Nrf2 normally binds to Keap1 (Kelch-like ECH-associated protein 1) in the cytoplasm
• Oxidative stress causes Nrf2 dissociation and nuclear translocation
• Nrf2 binds to Antioxidant Response Elements (ARE) in DNA
• This transcription activates >200 antioxidant and cytoprotective genes including:
• HO-1 (heme oxygenase-1): degrades pro-oxidant heme, produces biliverdin
• GCLM (glutamate-cysteine ligase modifier subunit): rate-limiting step in glutathione synthesis
• NQO1 (NAD(P)H quinone dehydrogenase 1): detoxification enzyme
• SOD (superoxide dismutase): scavenges superoxide radicals

Activation by Carbamate Derivatives

The ferulic acid carbamate derivatives activate Nrf2 through Keap1-Nrf2 dissociation[@lao2026]:

In vitro studies showed that compounds 5c, 5g, and 5h:

• Upregulated HO-1 expression in HT22 neuronal cells
• Increased GCLM levels, enhancing glutathione synthesis
• Reduced ROS accumulation in H₂O₂-challenged cells
• Protected against Aβ-induced toxicity in neuronal cultures

Neuroprotective Effects

In Vitro Results

In HT22 hippocampal neurons, the lead compounds demonstrated[@lao2026]:

In Vivo Efficacy

In Aβ transgenic C. elegans models, lead compounds demonstrated:

• Reduced paralysis: Improved locomotive function in Aβ-expressing worms
• Cognitive improvement: Enhanced learning and memory in behavioral assays
• Reduced oxidative stress: Decreased ROS markers in nervous tissue
• Good CNS drugability: Favorable pharmacokinetic properties for brain penetration

Molecular Docking

Computational studies confirmed that compound 5c:

• Binds to BuChE active site with favorable interactions (hydrogen bonds, hydrophobic contacts)
• Interacts with Keap1 at key cysteine residues (C151, C273, C288) that trigger Nrf2 release

Therapeutic Potential

Advantages of Dual-Targeting Approach

The ferulic acid carbamate derivatives offer several unique advantages:

Comparison with Existing AD Therapies

Clinical Translation Potential

Given the strong preclinical data:

• Phase I trials could assess safety, tolerability, and pharmacokinetics in healthy volunteers
• Phase II trials could evaluate cognitive endpoints in mild-to-moderate AD patients
• Combination potential: Could be combined with existing AChE inhibitors for enhanced effect

Cross-Linking

Related Mechanisms

• [Nrf2 Pathway](/mechanisms/nrf2-pathway) — Master regulator of antioxidant response
• [Nrf2 Activation in Parkinson's Disease](/mechanisms/nrf2-activators-parkinsons)
• [Oxidative Stress in AD](/mechanisms/oxidative-stress-comparison)
• [Nrf2-Keap1 Pathway](/mechanisms/nrf2-keap1-pathway)

Related Therapies

• [NRF2 Activator Therapy](/therapeutics/nrf2-activator-therapy) — Broader Nrf2 activation approaches
• [Antioxidant Therapy](/therapeutics/antioxidant-therapy-neurodegeneration)
• [Alpha-Lipoic Acid](/therapeutics/alpha-lipoic-acid-neurodegeneration) — Another antioxidant therapeutic
• [Curcumin Neurodegeneration](/therapeutics/curcumin-neurodegeneration) — Natural product with similar properties
• [Sulforaphane Nrf2 Neuroprotection](/therapeutics/sulforaphane-nrf2-neuroprotection)

Related Proteins/Genes

• [BCHE Gene](/proteins/bche-protein) — Butyrylcholinesterase gene
• [NRF2 Protein](/proteins/nrf2)
• [KEAP1 Protein](/proteins/keap1)
• [HO-1 Protein](/proteins/ho-1)
• [GCLM Protein](/proteins/gclm-protein)

Related Disease Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
• [Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: PVALB
• [Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
• [GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: GFAP
• [Excitatory Neuron Vulnerability via SLC17A7 Downregulation](/hypothesis/h-seaad-7f15df4c) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: SLC17A7
• [SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction](/hypothesis/h-seaad-v4-5a7a4079) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: SIRT3

Related Analyses:

• [Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) &#x1f504;
• [Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Ferulic Acid Carbamate Derivatives for Alzheimer's Disease discovered through SciDEX knowledge graph analysis: